bioRxiv preprint doi: https://doi.org/10.1101/2023.06.01.543292; this version posted August 4, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

Supplemental Figure 1: Schematic representations of antibody performance

(A) Schematic representations of a successful antibody (left schematic), specific, non-selective antibody (middle schematic), and a non-successful antibody (right schematic) for WB. (B) Schematic representations of a successful antibody (left schematic) and non-successful antibodies (middle and right schematics) for IP. (C) Schematic representation of the mosaic strategy used (left schematic). WT cells are labelled with a fluorescent cell dye (green), and KO cells are labelled with a different fluorescent cell dye (magenta) plated together as a mosaic. Schematic representations of a successful antibody (antibody #1) and a non-successful antibody (antibody #2) for IF are shown.

Supplemental Figure 2: Analysis of antibody performance by manufacturer's catalogue recommendation

Percentage of successful or unsuccessful antibodies for the indicated applications are shown using a bar graph with stacked columns. Antibodies were divided according to whether they were recommended or not recommended by the manufacturers for the indicated applications. The percentage corresponding to each section of the bar graph is shown in the graph, and the total number of antibodies represented in each category is indicated above the corresponding bar.

Supplemental Figure 3: Actions taken from participating companies

The percentage of antibodies removed from the market, or for which catalogue recommendations were modified following assessment of our data by our antibody manufacturing partners. The number of antibodies represented in each category is indicated above the corresponding bar.

Supplemental Figure 4: Correlation of antibody performance between applications

(**A**) Representation of a 2 x 2 contingency table used to apply the McNemar Test as well as the equation of the chi-square (X^2) statistic used. Analysis of antibody performance correlation, represented as a contingency table and as a double y-axis graph between (**B**) WB and IP, (**C**) IF and IP and (**D**) IF and WB. n/s = non-significant



Ayoubi et al., Supplemental Figure 1



bioRxiv preprint doi: https://doi.org/10.1101/2023.06.01.3452929; the wersoft besch Asgust 4, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv e license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 international license.



Α

bioRxiv preprint doi: https://doi.org/10.1101/2023.06.01.543292; this version posted August 4, 2023. The copyright holder for this preprint (which wappficting by #2 rreview) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

		fail	pass	
application #1	fail	а	b	v ² = -
	pass	С	d	^

<u>(b-c)²</u> b+c

С

В

	IP: fail	IP: pass
WB: fail	190	101
WB: pass	126	112
	χ²=1.3 n>0.1	

	IP: fail	IP: pass
IF: fail	255	98
IF: pass	61	115
	χ²=8.6	

p<0.005









